{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:30:14Z","timestamp":1773012614261,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"am","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.therap.2024.07.003","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T10:07:09Z","timestamp":1721988429000},"page":"327-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A biological pharmacology network to secure the risk of drug\u2013drug interaction with nirmatrelvir\/ritonavir"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-3629","authenticated-orcid":false,"given":"Florian","family":"Lemaitre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidvine","family":"Boland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Tron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Lelong-Boulouard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Gandia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Goirand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Gambier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Boglione-Kerrien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Franck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Lalanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Devresse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien","family":"Briol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Haufroid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Cl\u00e9mence","family":"Verdier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.07.003_bib0105","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2024.07.003_bib0110","doi-asserted-by":"crossref","first-page":"12609","DOI":"10.1038\/s41598-022-16964-z","article-title":"In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5","volume":"12","author":"Touret","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.therap.2024.07.003_bib0115","series-title":"A study of immune system proteins in participants with mild to moderate COVID-19 illness (BLAZE-4","author":"Clinicaltrials.gov","year":"2022"},{"key":"10.1016\/j.therap.2024.07.003_bib0120","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/FTD.0000000000000761","article-title":"Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug\u2013drug interactions","volume":"42","author":"Elens","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2024.07.003_bib0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/FTD.0000000000001014","article-title":"Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir\/ritonavir in patients with COVID-19","volume":"45","author":"Lemaitre","year":"2023","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2024.07.003_bib0130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.therap.2022.03.005","article-title":"Management of drug-drug interactions with nirmatrelvir\/ritonavir in patients treated for COVID-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT)","volume":"77","author":"Lemaitre","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.07.003_bib0135","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.therap.2023.03.001","article-title":"Nirmatrelvir\/ritonavir (Paxlovid\u00ae): French pharmacovigilance survey 2022","volume":"78","author":"Bihan","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.07.003_bib0140","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.ekir.2022.08.026","article-title":"Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2","volume":"7","author":"Devresse","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.therap.2024.07.003_bib0145","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/TP.0000000000004430","article-title":"First experience of optimization of tacrolimus therapeutic drug monitoring in a patient cotreated with nirmatrelvir\/ritonavir: how microsampling approach changes everything","volume":"107","author":"Golbin","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.therap.2024.07.003_bib0150","series-title":"Paxlovid. Summary of products characteristics","author":"EMA","year":"2024"},{"key":"10.1016\/j.therap.2024.07.003_bib0155","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","article-title":"Drug\u2013drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors","volume":"52","author":"Chauvin","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.therap.2024.07.003_bib0160","first-page":"305","article-title":"Managing drug\u2013drug interaction between ombitasvir, paritaprevir\/ritonavir, dasabuvir, and mycophenolate mofetil","volume":"39","author":"Lemaitre","year":"2017","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2024.07.003_bib0165","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/cpt.2805","article-title":"A case report of safe coadministration of amiodarone with short-term treatment nirmatrelvir-ritonavir","volume":"113","author":"Sluijters","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2024.07.003_bib0170","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2217\/fvl-2022-0060","article-title":"Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid\u2122 therapy","volume":"17","author":"Vuorio","year":"2022","journal-title":"Future Virol"},{"key":"10.1016\/j.therap.2024.07.003_bib0175","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-023-07538-w","article-title":"Influence of a short course of ritonavir used as booster in antiviral therapies against SARS-CoV-2 on the exposure of atorvastatin and rosuvastatin","author":"Krohmer","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.therap.2024.07.003_bib0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2015.01.026","article-title":"Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir\/ritonavir, ombitasvir, and dasabuvir","volume":"63","author":"Menon","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.therap.2024.07.003_bib0185","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1177\/0091270011427907","article-title":"Influence of SLCO1B1 polymorphisms on the drug\u2013drug interaction between darunavir\/ritonavir and pravastatin","volume":"52","author":"Aquilante","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.07.003_bib0190","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/FTD.0000000000001014","article-title":"Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir\/ritonavir in patients with COVID-19","volume":"45","author":"Lemaitre","year":"2023","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2024.07.003_bib0195","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40262-022-01158-7","article-title":"Yes we can (Use nirmatrelvir\/ritonavir even in high immunological risk patients treated with immunosuppressive drugs)!","volume":"61","author":"Lemaitre","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.therap.2024.07.003_bib0200","first-page":"e50469","article-title":"Drug\u2013drug interactions between COVID-19 treatments and psychotropic medications: an updated study","volume":"15","author":"Boppana","year":"2023","journal-title":"Cureus"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T17:14:48Z","timestamp":1747761288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724000817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0040595724000817"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.07.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A biological pharmacology network to secure the risk of drug\u2013drug interaction with nirmatrelvir\/ritonavir","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}